
Biotechnology Direct Investments
US, Europe and GCC
Life Sciences Growth Capital
Licorne Gulf invests direct and syndicated capital into commercial-stage biotechnology, biopharma manufacturing, and regulated diagnostic platforms across the United States, Europe, and the Gulf. We back proven revenue-generating leaders—no early-stage startups.
SECTOR FOCUS
Six Core Biotechnology Verticals
We deploy growth equity and cross-border expansion capital into scaled, clinically validated life sciences operators across the US, Europe, and GCC.

Biopharma and Biologics Production
We invest in commercial biologic, biosimilar, and specialty therapeutic producers with FDA/EMA regulatory approvals, validated commercial sales, and regional capacity expansion demand.

Clinical Genomics and Precision Medicine
We back scaled genomic sequencing labs, precision oncology platforms, and population-health data systems supporting national healthcare modernization across Europe and the GCC.

Diagnostics and Molecular Testing
We fund high-throughput diagnostic labs, point-of-care molecular testing manufacturers, and clinical reagent suppliers serving hospital networks and sovereign health programs.

MedTech Devices and Imaging
We partner with revenue-generating medical device OEMs, surgical robotics platforms, and clinical imaging providers scaling distribution across Gulf hospital systems.

Pharma CDMO and Fill-Finish
We finance contract development and manufacturing organizations (CDMOs), sterile fill-finish plants, and localized pharmaceutical packaging infrastructure serving MENA demand.

Bioprocessing and Lab Automation
We deploy capital into upstream bioprocessing consumables, cleanroom instrumentation, and laboratory automation systems powering commercial GMP life sciences production.
INVESTMENT MANDATE
Transaction Criteria & Deal Structuring
How we structure growth equity, licensing joint ventures, and strategic acquisitions linking US and European life sciences IP with Gulf healthcare capacity.

Investment Criteria (US, Europe & GCC)
We target commercial-stage biotech, CDMO, and medtech enterprises only—never pre-revenue concept startups. Candidates must demonstrate regulatory approvals, commercial revenue, and protected IP.

GCC Market Entry & Joint Ventures
For Western life sciences companies entering Saudi Arabia, Qatar, the UAE, and Bahrain, we structure local GMP fill-finish JVs, SFDA/regulatory pathways, and hospital procurement access.

Co-Investment & Strategic Buyouts
We co-invest alongside healthcare funds, family offices, pharmaceutical groups, and sovereign health entities across expansion rounds, carve-outs, and strategic buyouts.

Governance & Capital Alignment
Transactions are structured under UK and Swiss institutional holding governance to align founder equity incentives with long-term value creation and clean cap-table discipline.

Direct Investment Committee
Every submission is evaluated directly by Licorne Gulf managing principals. Initial Mandate screening is typically completed within 5–10 business days before formal diligence.

Confidentiality & IP Protection
All clinical trial dossiers, regulatory filings, patent portfolios, and financial models are evaluated strictly in-house under NDA and never shared with external brokers.
GCC VALUE CREATION
US & Europe to GCC Scale
"We pair growth capital with GMP localization and sovereign healthcare market access across Saudi Arabia, Qatar, and the UAE."
GCC governments are investing billions into domestic pharmaceutical security, precision-genomics programs, and local biologics manufacturing—creating high demand for commercial US and European life sciences platforms.
Licorne Gulf provides experienced local execution on the ground, helping scaled biotech and medtech firms navigate SFDA and GCC regulatory registration, build local manufacturing joint ventures, and win institutional tenders.

20+
YEARS GLOBAL REACH
FOUNDER & INVESTOR FAQ
Key Questions on Biotechnology Investments
Direct answers on investment mandate, GCC expansion support, co-investments, and confidential transaction review.

What biotech stages and companies do you target?
We invest strictly in scaled, revenue-generating biopharma, diagnostics, CDMO, and regulated medtech companies—never pre-clinical startups or unvalidated concepts.

What transaction structures do you provide?
Licorne Gulf deploys direct growth equity, GMP facility expansion capital, co-investment tranches, licensing joint ventures, and strategic buyouts.

Do US or European firms need GCC approvals beforehand?
No. Companies with established FDA or EMA approvals and commercial traction partner with us specifically to establish GCC distribution, SFDA registration, and local fill-finish JVs.

Do you invest in pre-revenue drug discovery startups?
No. Our mandate is focused strictly on scaled commercial operators with proven revenue, regulatory clearance, and clear profitability or commercial trajectory.

Can healthcare funds or family offices co-invest?
Yes. We regularly co-invest alongside life sciences venture-growth funds, pharmaceutical corporates, family offices, and sovereign partners.

How are clinical and IP documents kept confidential?
All proprietary technical data, clinical dossiers, and financials are reviewed exclusively inside our investment committee under NDA and UK/Swiss governance.
